研究单位：[1]Ruijin Hospital[2]Beijing InnoCare Pharma Tech Co., Ltd.[3]The first affiliated hospital of bengbu medical college,Bengbu,Anhui,China,233000[4]Anhui Provincal Cancer Hospital,Hefei,Anhui,China,230031[5]Beijing Hospital,Beijing,Beijing,China,100730[6]Chongqing University Cancer Hospital,Chongqing,Chongqing,China,400000[7]The Southwest Hospital of AMU,Chongqing,Chongqing,China,400000[8]Fujian Medical University Union Hospital,Fuzhou,Fujian,China,350001[9]The First Affiliated Hospital Of XIAMEN University,Xiamen,Fujian,China,361003[10]Gansu Provincial Cancer Hospital,Lanzhou,Gansu,China,730050[11]The First People's Hospital of Foshan,Foshan,Guangdong,China,528000[12]Guangdong General Hospital,Guangzhou,Guangdong,China,510180[13]ZhuJiang Hospital of Southern Medical University,Guangzhou,Guangdong,China,510280[14]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China,510700[15]PEKING University SHENZHEN Hospital,Shenzhen,Guangdong,China,518036[16]Sun Yat-sen University Cancer Center Internal medicine department,Guandong,Guangzhou,China,510060[17]Affiliated Hospital of Hebei University,Baoding,Hebei,China,050031[18]The Second Hospital of Hebei Medical University,Shijia Zhuang,Hebei,China,050000[19]The First Affiliated Hospital of Henan University of science and Technology,Luoyang,Henan,China,450052[20]Henan Cancer Hospital,Zhengzhou,Henan,China,450008[21]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052[22]Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430023[23]Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430030[24]The Second Xiangya Hospital of Central South University,Changsha,Hunan,China,410011[25]Hunan Cancer Hospital,Changsha,Hunan,China,410013[26]Chenzhou first people's Hospital,Chenzhou,Hunan,China,423099[27]The Affiliated Hospital of Nanjing University Medical School,Nanjing,Jiangsu,China,210008[28]The First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China,215006[29]Wuxi People's Hospital,Wuxi,Jiangsu,China,214043[30]Jiangxi Cancer Hospital,Nanchang,Jiangxi,China,330001[31]The First Affiliated Hospital Of Nanchang University,Nanchang,Jiangxi,China,330006[32]The Second Hospital of Dalian Medical University,Dalian,Liaoning,China,116023[33]The First Hospital of China Medical University,Shenyang,Liaoning,China,110002[34]Qilu Hospital Of Shandong University,Jinan,Shandong,China,250000[35]Provincial Hospital Affiliated to Shandong First Medical University,Jinan,Shandong,China,250021[36]The Affiliated Hospital of Qingdao University,Qingdao,Shandong,China,266400[37]Shanghai Changzheng Hospital,Shanghai,Shanghai,China,200003[38]Ruijin Hospital, Shanghai Jiaotong University School of Medicine,Shanghai,Shanghai,China,200025[39]Shanghai 6th People's Hospital,Shanghai,Shanghai,China,201306[40]The first Affiliated Hospital Of Xi'an Jiaotong University,Xi'an,Shanxi,China,710004[41]The Second Affiliated Hospital Of Xi'an Jiaotong University,Xi'an,Shanxi,China,710004[42]West China Hospital Sichuan University,Chengdu,Sichuan,China,610000[43]Tianjin Cancer Hospital,Tianjin,Tianjin,China,300060[44]Affiliated Cancer Hospital of Xinjiang Medical University,Ürümqi,Xinjiang,China,830000[45]The first affiliated Hospital Zhejiang University School Of Medicine,Hangzhou,Zhejiang,China,310003[46]Sir Run Run Shaw Hospital Zhejiang University School Of Medicine,Hangzhou,Zhejiang,China,310016[47]Shaoxing People's Hospital,Shaoxing,Zhejiang,China,312000
研究目的：
The purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP regimen versus placebo with R-CHOP in the treatment of treatment-naïve patients with MCD subtype DLBCL.
